Uworld RxPrep: Acute Coronary Syndromes

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/52

encourage image

There's no tags or description

Looks like no tags are added yet.

53 Terms

1
New cards

What causes Acute Coronary Syndrome (ACS) and what does it lead to?

Cause: Plaque buildup (atherosclerosis) in the coronary arteries that ruptures, leading to clot (thrombus) formation and sudden, reduced blood flow (ischemia) to the heart. Result: An imbalance between myocardial oxygen supply and demand, causing symptoms and/or cardiac muscle cell death (myocardial necrosis).

2
New cards

What are the non-modifiable risk factors for ACS?

Age: Males > 45 years; females > 55 years (or early hysterectomy). Family History: First-degree relative with a coronary event before age 55 (male) or age 65 (female).

3
New cards

What are the modifiable and chronic condition risk factors for ACS?

Smoking, hypertension, chronic coronary disease (e.g., stable angina, coronary artery disease), dyslipidemia, diabetes, physical inactivity, and heavy alcohol consumption.

4
New cards

What are the classic signs and symptoms of ACS?

Chest pain: Discomfort, pressure, or squeezing lasting >= 10 minutes (may radiate to the arms, back, neck, jaw, or epigastric region). Other symptoms: Severe dyspnea, diaphoresis, syncope/presyncope, and/or palpitations.

5
New cards

Which patient populations are less likely to experience classic ACS symptoms?

Females, older adults, and patients with diabetes.

6
New cards

What can precipitate ACS symptoms?

Symptoms can occur at rest or be triggered by minimal exertion, exercise, cold weather, extreme emotions, stress, or sexual intercourse.

7
New cards

How should a patient use prescribed sublingual nitroglycerin (NTG) for chest pain?

Take one dose every 5 minutes for up to three doses. If chest pain does not improve or worsens after taking NTG, call 911.

8
New cards

What conditions are encompassed under ACS, and how are they differentiated?

Categories: ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation acute coronary syndromes (NSTE-ACS), which includes unstable angina (UA) and non-ST-segment elevation myocardial infarction (NSTEMI). Differentiated by: ECG findings, detection of cardiac enzymes, and the extent of blockage in the affected artery.

9
New cards

What are the immediate diagnostic and transport protocols for suspected ACS/STEMI?

12-lead ECG: Must be performed and evaluated within 10 minutes of first medical contact (including in an ambulance). STEMI Transport: Urgently transport patients to a hospital with percutaneous coronary intervention (PCI) capability, if possible.

10
New cards

Which biomarkers are used to diagnose ACS, and what is the testing protocol?

Primary biomarkers: Cardiac troponins I and T (TnI and TnT) are the most sensitive and specific; they should be obtained at presentation (preferably via a high-sensitivity assay). Secondary biomarkers: Creatine kinase myocardial isoenzyme (CK-MB) and myoglobin (less sensitive). Nondiagnostic initial tests: Repeat ECG and cardiac troponin levels to detect delayed changes.

11
New cards

How do UA, NSTEMI, and STEMI compare across symptoms, cardiac enzymes, ECG changes, and artery blockage?

Symptoms: Chest pain for all three (UA, NSTEMI, and STEMI). Cardiac Enzymes: Negative in UA; positive in NSTEMI and STEMI. ECG Changes: None or transient ischemic changes (ST-segment depression and/or prominent T-wave inversion) in UA and NSTEMI; ST-segment elevation (meeting defined criteria in >= 2 contiguous leads) in STEMI. Blockage: Partial blockage in UA and NSTEMI; complete blockage in STEMI.

12
New cards

What is the overall goal of ACS treatment, and what are the main invasive revascularization procedures?

Goal: Provide immediate relief of ischemia and prevent MI expansion and death. Percutaneous Coronary Intervention (PCI): A coronary revascularization procedure that inflates a small balloon inside a coronary artery to widen it and improve blood flow, often placing a metal mesh stent to keep the artery open. Coronary Artery Bypass Grafting (CABG): A surgical method of reperfusion considered in select patients (e.g., multivessel disease).

13
New cards

How does invasive vs. medical management differ between NSTE-ACS and STEMI?

NSTE-ACS: Can be treated with medications alone (medical management) or with an invasive strategy (PCI or CABG). STEMI: Requires blocked arteries to be opened as quickly as possible using PCI or fibrinolysis.

14
New cards

What are the target timeframes for PCI and fibrinolytic therapy in STEMI management?

PCI (Preferred): Must be performed within 90 minutes of first medical contact (optimal door-to-balloon time), or within 120 minutes if transfer to a PCI-capable facility is required. Fibrinolytic Therapy: Recommended if PCI is not possible within 120 minutes of first medical contact; should be administered within 30 minutes of hospital arrival (door-to-needle or door-to-lysis time).

15
New cards

What are the three main drug classes used in combination after PCI or fibrinolysis, and how do they work?

Antianginals: Decrease myocardial oxygen demand or increase supply (blood flow) to relieve ischemia. Antiplatelets: Inhibit platelet aggregation to prevent clot formation/growth. Anticoagulants: Inhibit clotting factors to prevent clot formation/growth.

16
New cards

What does the mnemonic MONA-GAP-BA stand for in ACS drug treatment?

Morphine, Oxygen, Nitrate, Aspirin, GPIIb/IIIa antagonist, Anticoagulant, P2Y12 inhibitor, Beta-blocker, ACE inhibitor or ARB.

17
New cards

How is MONA-GAP-BA applied to NSTE-ACS versus STEMI?

NSTE-ACS: MONA-GAP-BA +/- PCI. STEMI: MONA-GAP-BA + PCI or fibrinolytic (PCI preferred).

18
New cards

Why should NSAIDs (except aspirin) be avoided during hospitalization for ACS?

Both nonselective and COX-2-selective NSAIDs increase the risk of mortality, reinfarction, hypertension, cardiac rupture, renal insufficiency, and heart failure.

19
New cards

What are the four "MONA" drugs given immediately (as needed) for ACS?

Morphine Sulfate, Oxygen, Nitrate, and Aspirin.

20
New cards

What is the clinical benefit and key clinical guidance for Morphine Sulfate in ACS?

Benefit: Provides pain relief and helps anxiety. Guidance: Not for routine use (diminishes antiplatelet effects); reserve for patients with unacceptable chest discomfort despite other treatments. Monitor for hypotension, N/V, bradycardia, sedation, and respiratory depression.

21
New cards

When should Oxygen be administered in ACS, and what is its benefit?

Benefit: Increases myocardial oxygen supply to decrease anginal symptoms. Indication: Administer if arterial oxygen saturation is < 90% or if the patient has respiratory distress.

22
New cards

What are the clinical benefits, dosing, and contraindications for Nitrates in ACS?

Benefit: Antianginal that dilates coronary arteries, improves collateral blood flow, and decreases preload and afterload (modestly) to reduce chest pain. Dosing: Sublingual NTG (0.3 or 0.4 mg every 5 minutes x 3 doses) if not already given and the patient has persistent chest pain, hypertension, or heart failure; IV NTG can be considered if symptoms persist. Contraindications: Do not use IV NTG if SBP < 90 mmHg, HR < 50 bpm, or with a right ventricular infarction. PDE-5 inhibitors are contraindicated with NTG.

23
New cards

What is the acute and maintenance dosing protocol for Aspirin in ACS?

Benefit: Inhibits platelet aggregation. Acute Dose: Non-enteric-coated, chewable aspirin (162–325 mg) given immediately to all patients if no contraindications exist (do not use extended-release aspirin products). Maintenance: 75–100 mg daily continued indefinitely. Consider desensitization when stable if the patient is intolerant.

24
New cards

What are the three "GAP" drug classes given next in ACS (guided by PCI vs. fibrinolysis vs. medical management)?

GPIIb/IIIa Receptor Antagonist, Anticoagulant, and P2Y12 Inhibitor.

25
New cards

What are the mechanisms, examples, and duration of use for the GAP drugs in ACS?

GPIIb/IIIa Receptor Antagonists: Inhibit platelet aggregation; includes eptifibatide and tirofiban. Anticoagulants: Inhibit clotting factors and can reduce infarct size; includes enoxaparin, UFH, bivalirudin, and fondaparinux (continued short-term only, such as until revascularization or hospital discharge). P2Y12 Inhibitors: Inhibit platelet aggregation; includes clopidogrel, prasugrel, ticagrelor, and cangrelor.

26
New cards

What are the clinical benefits and initiation guidelines for Beta-Blockers ("B" in BA) in ACS?

Benefits: Antianginal that decreases BP, HR, and contractility; decreases ischemia, reinfarction, and arrhythmias; prevents cardiac remodeling; increases long-term survival. Initiation: Start an oral, low-dose beta-blocker (beta-1 selective without intrinsic sympathomimetic activity preferred) within the first 24 hours unless contraindicated (e.g., decompensated heart failure, cardiogenic shock, HR < 45 bpm). Special Cases & Alternatives: Use bisoprolol, metoprolol succinate, or carvedilol if the patient has concomitant, stable HFrEF. An IV beta-blocker or an oral long-acting non-dihydropyridine CCB (verapamil or diltiazem) are alternative options in some situations.

27
New cards

What are the clinical benefits and initiation guidelines for ACE Inhibitors or ARBs ("A" in BA) in ACS?

Benefits: Inhibits angiotensin II activity, prevents cardiac remodeling, and decreases preload and afterload. Initiation: Start an oral ACE inhibitor or ARB in all patients with LVEF < 40%, hypertension, or diabetes unless contraindicated (use in all other patients may be reasonable). Precaution: Do not use an IV ACE inhibitor within the first 24 hours due to the risk of hypotension.

28
New cards

What are the four classes of antiplatelet drugs and their mechanisms of action?

Aspirin: Irreversibly inhibits COX-1 and COX-2, decreasing the production of thromboxane A2 (TXA2), an inducer of platelet aggregation. P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor, cangrelor): Bind to platelet adenosine diphosphate (ADP) P2Y12 receptors, preventing ADP-mediated activation of the GPIIb/IIIa receptor complex. GPIIb/IIIa receptor antagonists (eptifibatide, tirofiban): Block the platelet glycoprotein IIb/IIIa receptor (the binding site for fibrinogen, von Willebrand factor, and other ligands). Protease-activated receptor-1 (PAR-1) antagonist (vorapaxar): Inhibits PAR-1, preventing thrombin- and thrombin receptor agonist peptide-induced platelet aggregation.

29
New cards

How do clopidogrel, prasugrel, and ticagrelor differ in their classification, activation, receptor binding, and potency?

Clopidogrel & Prasugrel: Structurally similar thienopyridines; both are prodrugs that irreversibly bind to the P2Y12 receptor. Ticagrelor: Not a prodrug and has reversible binding to the P2Y12 receptor. Potency: Ticagrelor and prasugrel have more potent antiplatelet activity compared to clopidogrel.

30
New cards

What is Dual Antiplatelet Therapy (DAPT), how is it dosed initially, and which P2Y12 inhibitors are preferred for PCI vs. fibrinolysis?

DAPT Definition: Using a P2Y12 inhibitor together with aspirin after ACS. Dosing: Requires a higher one-time loading dose for the P2Y12 inhibitor, followed by a maintenance dose. Agent Selection: Ticagrelor or prasugrel are preferred with PCI; clopidogrel is preferred with fibrinolysis.

31
New cards

What is the brand name, formulation, and maintenance dose for Clopidogrel?

Brand Name: Plavix. Formulation: Tablet. Maintenance Dose: 75 mg PO daily.

32
New cards

What is the Boxed Warning for Clopidogrel (Plavix)?

Clopidogrel is a prodrug whose effectiveness depends on conversion to an active metabolite primarily by CYP450 2C19. CYP2C19 poor metabolizers experience a reduced antiplatelet effect compared to patients with normal CYP2C19 function. Tests to check CYP2C19 genotype can help guide therapy, and alternative treatments should be considered in identified poor metabolizers.

33
New cards

What are the contraindications and key warnings for Clopidogrel (Plavix)?

Contraindications: Active serious bleeding (e.g., GI bleed, intracranial hemorrhage). Warnings: Bleeding risk (stop 5 days prior to elective surgery); do not use with omeprazole or esomeprazole; premature discontinuation (increases risk of cardiovascular events); thrombotic thrombocytopenic purpura (TTP).

34
New cards

What is the brand name, formulation, and maintenance dosing for Prasugrel?

Brand Name: Effient. Formulation: Tablet. Maintenance Dose: 10 mg PO daily (reduce to 5 mg daily if patient weighs < 60 kg or is age >= 75 years).

35
New cards

What are the Boxed Warnings, contraindications, warnings, and storage notes for Prasugrel (Effient)?

Boxed Warnings: Significant, sometimes fatal, bleeding; not recommended in patients >= 75 years due to high bleeding risk, unless considered high risk (diabetes or prior MI); do not initiate if CABG is likely; stop at least 7 days prior to elective surgery. Contraindications: Active serious bleeding, history of stroke or TIA. Warnings: Bleeding risk, premature discontinuation (increases risk of CV events), TTP. Notes: Protect from moisture; dispense in the original container.

36
New cards

What is the brand name, formulation, and maintenance dosing for Ticagrelor?

Brand Name: Brilinta. Formulation: Tablet. Maintenance Dose: 90 mg PO BID for 1 year, then 60 mg BID (if continued).

37
New cards

What are the Boxed Warnings for Ticagrelor (Brilinta)?

Significant, sometimes fatal, bleeding. After the initial aspirin dose of 162–325 mg, do not exceed a maintenance aspirin dose of 100 mg daily because higher daily doses reduce the effectiveness of ticagrelor. Do not initiate if undergoing urgent CABG; stop 5 days before any surgery.

38
New cards

What are the contraindications, warnings, and side effects of Ticagrelor (Brilinta)?

Contraindications: Active serious bleeding, history of intracranial hemorrhage. Warnings: Bleeding risk, severe hepatic impairment, bradyarrhythmias, premature discontinuation (increases risk of CV events), TTP. Side Effects: Bleeding, dyspnea (> 10%), increased SCr, increased uric acid.

39
New cards

What is the brand name, formulation, indication, and clinical administration notes for Cangrelor?

Brand Name: Kengreal. Formulation: Injection. Use: Only for short-term use before or during PCI if an oral P2Y12 inhibitor was not administered. Contraindication & Side Effect: Significant active bleeding (contraindication); bleeding (side effect). Notes: Effects last up to 1 hour after discontinuation. Transition to an oral P2Y12 inhibitor after PCI (timing depends on the oral agent used, but a loading dose is required for all).

40
New cards

What are the general bleeding interaction rules for P2Y12 inhibitors?

Most interactions result from additive effects with drugs that increase bleeding risk, such as NSAIDs, anticoagulants, SSRIs, and SNRIs. If an ACS patient experiences bleeding on a P2Y12 inhibitor, manage it without discontinuing the P2Y12 inhibitor if possible, as stopping it (especially within the first few months after ACS) increases the risk of subsequent cardiovascular events.

41
New cards

What are the specific metabolic drug interactions for Clopidogrel and Ticagrelor?

Clopidogrel: Avoid combining with the CYP2C19 inhibitors esomeprazole and omeprazole due to decreased antiplatelet effect; use caution with other CYP2C19 inhibitors. Ticagrelor: Major CYP3A4 substrate; avoid use with strong CYP3A4 inhibitors or inducers, and avoid simvastatin and lovastatin doses > 40 mg/day.

42
New cards

What are the Glycoprotein IIb/IIIa receptor antagonists, how are they used, and what are their main side effects?

Drugs: Eptifibatide and tirofiban. Mechanism & Use: Reversibly block the GPIIb/IIIa receptor on platelets. These IV medications can be used along with DAPT and an anticoagulant for patients receiving a PCI +/- stent, though they are not administered routinely. Side Effects: Bleeding and thrombocytopenia.

43
New cards

What is Vorapaxar, what is its clinical indication, and when is it NOT used?

Class: Protease-activated receptor-1 (PAR-1) antagonist. Use: Used in combination with aspirin and/or clopidogrel in patients with a history of MI or peripheral arterial disease (PAD) to reduce thrombotic cardiovascular events (e.g., CV death, MI, stroke). Restriction: It is not used during acute ACS management.

44
New cards

How do fibrinolytics work, and what are the exact clinical criteria and timing for their use in STEMI?

Mechanism: Cause fibrinolysis (clot breakdown) by binding to fibrin and converting plasminogen to plasmin (also known as plasminogen activators). Criteria: Used only for patients with STEMI who are < 12 hours from symptom onset when the anticipated delay to PCI is >= 120 minutes. Target Timing: Must be administered within 30 minutes of hospital arrival (door-to-needle or door-to-lysis time) to improve survival.

45
New cards

What are the three fibrinolytic drugs, their brand names, and their dosing/administration regimens for STEMI?

Alteplase (Activase): Recombinant tissue plasminogen activator (tPA, rtPA—though "tPA" is not recommended by ISMP due to error risk); weight-based IV infusion administered over 90 minutes. (Note: Cathflo Activase is a single-use 2 mg vial used to restore function of potentially clotted central lines/devices). Tenecteplase (TNKase): Weight-based single IV bolus. Reteplase (Retavase): Two fixed-dose IV boluses administered 30 minutes apart.

46
New cards

What are the contraindications, side effects, and monitoring parameters for Fibrinolytics?

Contraindications: Active internal bleeding or bleeding diathesis; history of recent stroke; any prior intracranial hemorrhage (ICH); recent intracranial or intraspinal surgery or trauma (within the last 2–3 months); intracranial neoplasm, arteriovenous malformation, aneurysm, or suspected aortic dissection; severe uncontrolled hypertension (unresponsive to emergency therapy). Side Effects: Bleeding (including ICH). Monitoring: Hgb, Hct, and signs/symptoms of bleeding. Note: Alteplase contraindications and dosing differ when used for ischemic stroke.

47
New cards

What lifestyle modifications should be included in counseling for secondary prevention after ACS?

Smoking cessation, managing chronic conditions (e.g., hypertension, diabetes), limiting alcohol intake, increasing physical activity, and consuming a healthy diet.

48
New cards

What are the secondary prevention guidelines for Aspirin and Nitroglycerin after ACS?

Aspirin: Continue indefinitely (typically 81 mg per day). Nitroglycerin: Continue indefinitely as sublingual (SL) tablets or spray PRN.

49
New cards

How long should a P2Y12 inhibitor be continued after ACS, and which agents are preferred based on management strategy?

Duration: Typically continued with aspirin (DAPT) for at least 12 months; continuation beyond 12 months may be considered if the patient tolerates DAPT and is not at high risk of bleeding. Medical management: Ticagrelor (preferred) or clopidogrel. Managed with fibrinolysis: Clopidogrel. Managed with PCI: Ticagrelor or prasugrel. High bleeding risk after PCI: Can implement a bleeding risk reduction strategy >= 1 month after PCI (e.g., transition to ticagrelor monotherapy or de-escalate P2Y12 inhibitor potency by switching to clopidogrel).

50
New cards

What are the secondary prevention guidelines for Beta-Blockers, ACE Inhibitors/ARBs, and Aldosterone Antagonists after ACS?

Beta-Blocker: Continue indefinitely in patients with heart failure or if needed to manage hypertension or arrhythmia. ACE Inhibitor or ARB: Continue indefinitely if EF

51
New cards

What is the lipid-lowering therapy protocol for secondary prevention after ACS?

High-Intensity Statin: Continue indefinitely for all patients. Nonstatin Therapy: Consider adding a nonstatin lipid-lowering therapy (e.g., ezetimibe) if on a maximally-tolerated statin and LDL >= 70 mg/dL.

52
New cards

How should chronic musculoskeletal pain be managed in post-ACS patients?

Consider alternative therapies (e.g., acetaminophen, tramadol) before using NSAIDs. If an NSAID is needed, it is reasonable to use a nonselective NSAID such as naproxen (lowest cardiovascular risk). COX-2 selective NSAIDs have a higher cardiovascular risk and should be avoided.

53
New cards

How is antithrombotic therapy managed in post-ACS patients who also require anticoagulation (e.g., for atrial fibrillation)?

Duration: Use triple antithrombotic therapy for the shortest time possible. Preferred Agent: Clopidogrel is the preferred P2Y12 inhibitor for triple therapy. De-escalation: Consider transitioning to dual therapy (anticoagulant + P2Y12 inhibitor) after 1–4 weeks. GI Protection: A proton pump inhibitor (PPI) is recommended for patients with a high risk of GI bleeding while taking triple antithrombotic therapy.